Peptide Initiative

Peptides · Peptide comparison

Mazdutide vs Survodutide

Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.

Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeMazdutide4–4 mgSurvodutide3.6–3.6 mg
FrequencyMazdutideOnce dailySurvodutideOnce daily
AdministrationMazdutideSubcutaneous injectionSurvodutidesubcutaneous injection
Cycle lengthMazdutideOngoing/indefiniteSurvodutideOngoing/indefinite
Onset speedMazdutideModerate (1-2 weeks)SurvodutideModerate (1-2 weeks)
Evidence levelMazdutideStrong human trials (Phase 3 or FDA approved)SurvodutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Loss

Mazdutide98%
SurvodutideNo recorded rating

Blood Sugar Control

Mazdutide96%
Survodutide8%

Metabolic Health

Mazdutide90%
Survodutide9%

Weight Management

MazdutideNo recorded rating
Survodutide9%

Technical data

Compound specifications

Mazdutide

Molecular formula
C210H322N46O67
Molecular weight
4563.1 Da
Half-life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
CAS number
2259884-03-0

Survodutide

Molecular formula
C192H289N47O61
Molecular weight
4,231.6 Da
Half-life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS number
2805997-46-8

Protocols

Dosing compared

Mazdutide

Subcutaneous

  • Initial titration weeks1.5 mgOnce weekly · Initial titration weeksGLORY-1 Phase 3 starting dose; mazdutide was initiated at 1.5 mg once weekly and titrated stepwise toward the target maintenance dose to limit GI effects [6].
  • Weeks 32-484 mgOnce weekly · Maintenance (32-48 weeks in trial)GLORY-1 Phase 3 maintenance dose; produced about 11-12% mean body-weight reduction. Approved in China at this strength for weight management [6].
  • Weeks 32-486 mgOnce weekly · Maintenance (32-48 weeks in trial)GLORY-1 Phase 3 higher maintenance dose; produced about 13-15% mean body-weight reduction. Approved in China at this strength alongside the 4 mg dose [6].

Survodutide

Subcutaneous

  • Initiation, part of a 20-week up-titration0.6 mgOnce weekly · Initiation, part of a 20-week up-titrationPhase 2 starting dose; gradual escalation reduces GI side effects [1].
  • 26-week maintenance after escalation3.6 mgOnce weekly · 26-week maintenance after escalationMaintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
  • 26-week maintenance after escalation4.8 mgOnce weekly · 26-week maintenance after escalationHighest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].

Applications

Best suited for

Mazdutide

Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. [6][7] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. [1][15] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. [6][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. [4][5] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Survodutide

Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Mazdutide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite

Uncommon

  • Vomiting
  • Injection Site Reactions

Serious

  • Acute Pancreatitis
  • Acute Cholecystitis and Biliary Disease
  • Severe Nausea and Gastrointestinal Intolerance

Survodutide

Common

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased Appetite

Uncommon

  • Constipation and Abdominal Pain

Serious

  • Acute Pancreatitis

Research status

Safety & evidence

Mazdutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Mazdutide (Innovent/Lilly GLP-1 and glucagon dual agonist) is approved in China for weight management and type 2 diabetes. [4] Its safety profile is dominated by gastrointestinal side effects, mostly mild to moderate. [7][11] Nausea/vomiting occur in 40-50% of subjects at higher doses; [7][12] weight loss averaging 12-18% observed. [6][7] Pancreatitis risk monitoring required; [9][10] calcitonin was monitored, with no values of 20 ng/L or higher in phase 2. [9] Heart rate increases 5-9 bpm; [9] no serious cardiac safety signals. Developmental program focuses on tolerability optimization.

Contraindications

  • Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
  • Known hypersensitivity to mazdutide or any formulation excipients
  • History of severe pancreatitis
  • Severe renal impairment (eGFR <15 mL/min) without clinical data

Survodutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial [1]; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial [6]) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to survodutide or excipients
  • History of pancreatitis (caution advised with GLP-1 receptor agonists)

Decision guide

Which is right for you?

Mazdutide

Choose Mazdutide if…

  • Individuals seeking substantial weight loss exceeding 15% body weight
  • Adults with type 2 diabetes requiring superior glycemic management
  • Patients with obesity-related metabolic comorbidities
  • Those seeking dual-mechanism metabolic therapy

Survodutide

Choose Survodutide if…

  • Significant body weight reduction in obesity
  • MASH/NASH resolution and liver fibrosis improvement
  • Type 2 diabetes management with concurrent weight loss goals
  • Enhanced metabolic outcomes through dual receptor engagement